{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T14:51:50Z","timestamp":1788360710506,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T00:00:00Z","timestamp":1639440000000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Wolman disease (WD), the rapidly progressive phenotype of lysosomal acid lipase (LAL) deficiency, presents in neonates with failure to thrive and hepatosplenomegaly, and leads to multi-organ failure and death before 12\u00a0months of age. In clinical trials, enzyme replacement therapy (ERT) with sebelipase alfa led to improved survival, growth and biological parameters in WD patients followed up to 5\u00a0years. Long-term follow-up and health-related quality of life (HRQoL) evaluation are lacking.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We performed a nationwide, retrospective study of sebelipase alfa in WD patients. Five patients with abolished LAL activity and bi-allelic <jats:italic>LIPA<\/jats:italic> mutations were included with a median follow-up of 7\u00a0years (1\u201310). ERT was initiated at a median age of 1\u00a0month (0\u20134). Infusion tolerance was excellent on the long-term with only one patient requiring systematic pre-medication. Cholestyramine, fat-soluble vitamin supplements and a specific diet (high in medium-chain triglycerides and low in long-chain fatty acids) were prescribed. Liver function tests, plasma lipid profiles, fat-soluble vitamin levels and growth parameters improved. Three patients transiently exhibited a neuromyopathic phenotype (footdrop gait, waddling walk or muscle fatigue) but electromyography and muscle strength testing were normal. At last follow-up, all patients were alive with normal growth parameters and a satisfactory HRQoL, no patient had special education needs, and one patient required parenteral nutrition since an acute gastroenteritis.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Early ERT initiation allowed 100% survival with positive outcomes. Very long-term follow-up and hematopoietic stem cell transplantation while on ERT should be evaluated to strengthen the benefits of sebelipase alfa.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-021-02134-3","type":"journal-article","created":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T10:02:55Z","timestamp":1639476175000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Sebelipase alfa enzyme replacement therapy in Wolman disease: a nationwide cohort with up to ten years of follow-up"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7605-9031","authenticated-orcid":false,"given":"Tanguy","family":"Demaret","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5272-4970","authenticated-orcid":false,"given":"Florence","family":"Lacaille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Wicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1826-2810","authenticated-orcid":false,"given":"Jean-Baptiste","family":"Arnoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1740-5990","authenticated-orcid":false,"given":"Juliette","family":"Bouchereau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Belloche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2190-6843","authenticated-orcid":false,"given":"Cyril","family":"Gitiaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6557-2331","authenticated-orcid":false,"given":"David","family":"Grevent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Broissand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalila","family":"Adjaoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Th\u00e9r\u00e8se","family":"Abi Warde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Plantaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6184-7270","authenticated-orcid":false,"given":"Soumeya","family":"Bekri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7107-1250","authenticated-orcid":false,"given":"Pascale","family":"de Lonlay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Brassier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,14]]},"reference":[{"issue":"9","key":"2134_CR1","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/S2468-1253(17)30052-3","volume":"2","author":"M Pericleous","year":"2017","unstructured":"Pericleous M, Kelly C, Wang T, Livingstone C, Ala A. Wolman\u2019s disease and cholesteryl ester storage disorder: the phenotypic spectrum of lysosomal acid lipase deficiency. Lancet Gastroenterol Hepatol. 2017;2(9):670\u20139.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2134_CR2","unstructured":"Hoffman EP, Barr ML, Giovanni MA, Murray MF. Lysosomal acid lipase deficiency. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, et al., editors. GeneReviews. Seattle: University of Washington; Updated 2016 Sep 1."},{"issue":"5","key":"2134_CR3","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1161\/ATVBAHA.119.312136","volume":"39","author":"F Li","year":"2019","unstructured":"Li F, Zhang H. Lysosomal acid lipase in lipid metabolism and beyond. Arterioscler Thromb Vasc Biol. 2019;39(5):850\u20136.","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"1","key":"2134_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1006\/geno.1996.0162","volume":"33","author":"C Aslanidis","year":"1996","unstructured":"Aslanidis C, Ries S, Fehringer P, B\u00fcchler C, Klima H, Schmitz G. Genetic and biochemical evidence that CESD and Wolman disease are distinguished by residual lysosomal acid lipase activity. Genomics. 1996;33(1):85\u201393.","journal-title":"Genomics"},{"issue":"7","key":"2134_CR5","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1016\/S0022-2275(20)32518-9","volume":"39","author":"F Pagani","year":"1998","unstructured":"Pagani F, Pariyarath R, Garcia R, Stuani C, Burlina AB, Ruotolo G, et al. New lysosomal acid lipase gene mutants explain the phenotype of Wolman disease and cholesteryl ester storage disease. J Lipid Res. 1998;39(7):1382\u20138.","journal-title":"J Lipid Res"},{"key":"2134_CR6","first-page":"66","volume":"6","author":"G Del Angel","year":"2019","unstructured":"Del Angel G, Hutchinson AT, Jain NK, Forbes CD, Reynders J. Large-scale functional LIPA variant characterization to improve birth prevalence estimates of lysosomal acid lipase deficiency. Hum Mutat. 2019;6:66.","journal-title":"Hum Mutat"},{"key":"2134_CR7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2147\/HMER.S201630","volume":"11","author":"G Strebinger","year":"2019","unstructured":"Strebinger G, Muller E, Feldman A, Aigner E. Lysosomal acid lipase deficiency\u2014early diagnosis is the key. Hepat Med Evid Res. 2019;11:79\u201388.","journal-title":"Hepat Med Evid Res"},{"issue":"5","key":"2134_CR8","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/gim.2015.108","volume":"18","author":"SA Jones","year":"2016","unstructured":"Jones SA, Valayannopoulos V, Schneider E, Eckert S, Banikazemi M, Bialer M, et al. Rapid progression and mortality of lysosomal acid lipase deficiency presenting in infants. Genet Med. 2016;18(5):452\u20138.","journal-title":"Genet Med"},{"issue":"1","key":"2134_CR9","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jhep.2018.09.028","volume":"70","author":"A Carter","year":"2019","unstructured":"Carter A, Brackley SM, Gao J, Mann JP. The global prevalence and genetic spectrum of lysosomal acid lipase deficiency: a rare condition that mimics NAFLD. J Hepatol. 2019;70(1):142\u201350.","journal-title":"J Hepatol"},{"issue":"6","key":"2134_CR10","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1016\/j.jhep.2013.02.014","volume":"58","author":"DL Bernstein","year":"2013","unstructured":"Bernstein DL, Hulkova H, Bialer MG, Desnick RJ. Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. J Hepatol. 2013;58(6):1230\u201343.","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"2134_CR11","first-page":"97","volume":"10","author":"W Krivit","year":"1992","unstructured":"Krivit W, Freese D, Chan KW, Kulkarni R. Wolman\u2019s disease: a review of treatment with bone marrow transplantation and considerations for the future. Bone Marrow transplant. 1992;10(Suppl 1):97\u2013101.","journal-title":"Bone Marrow transplant"},{"issue":"2","key":"2134_CR12","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.ymgme.2013.03.007","volume":"109","author":"A Yanir","year":"2013","unstructured":"Yanir A, Allatif MA, Weintraub M, Stepensky P. Unfavorable outcome of hematopoietic stem cell transplantation in two siblings with Wolman disease due to graft failure and hepatic complications. Mol Genet Metab. 2013;109(2):224\u20136.","journal-title":"Mol Genet Metab"},{"issue":"7","key":"2134_CR13","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/bmt.2009.57","volume":"44","author":"MM Gramatges","year":"2009","unstructured":"Gramatges MM, Dvorak CC, Regula DP, Enns GM, Weinberg K, Agarwal R. Pathological evidence of Wolman\u2019s disease following hematopoietic stem cell transplantation despite correction of lysosomal acid lipase activity. Bone Marrow Transpl. 2009;44(7):449\u201350.","journal-title":"Bone Marrow Transpl"},{"issue":"5","key":"2134_CR14","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/sj.bmt.1702557","volume":"26","author":"W Krivit","year":"2000","unstructured":"Krivit W, Peters C, Dusenbery K, Ben-Yoseph Y, Ramsay NK, Wagner JE, et al. Wolman disease successfully treated by bone marrow transplantation. Bone Marrow Transpl. 2000;26(5):567\u201370.","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"2134_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/bmt.2008.273","volume":"43","author":"J Tolar","year":"2009","unstructured":"Tolar J, Petryk A, Khan K, Bjoraker KJ, Jessurun J, Dolan M, et al. Long-term metabolic, endocrine, and neuropsychological outcome of hematopoietic cell transplantation for Wolman disease. Bone Marrow Transplant. 2009;43(1):21\u20137.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2134_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13023-017-0587-3","volume":"12","author":"SA Jones","year":"2017","unstructured":"Jones SA, Rojas-Caro S, Quinn AG, Friedman M, Marulkar S, Ezgu F, et al. Survival in infants treated with sebelipase Alfa for lysosomal acid lipase deficiency: an open-label, multicenter, dose-escalation study. Orphanet J Rare Dis. 2017;12(1):25.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2134_CR17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13023-020-01577-4","volume":"16","author":"S Vijay","year":"2021","unstructured":"Vijay S, Brassier A, Ghosh A, Fecarotta S, Abel F, Marulkar S, et al. Long-term survival with sebelipase alfa enzyme replacement therapy in infants with rapidly progressive lysosomal acid lipase deficiency: final results from 2 open-label studies. Orphanet J Rare Dis. 2021;16(1):13.","journal-title":"Orphanet J Rare Dis"},{"key":"2134_CR18","volume-title":"Auxologie, m\u00e9thodes et s\u00e9quences","author":"M Semp\u00e9","year":"1979","unstructured":"Semp\u00e9 M, P\u00e9dron G, Roy-Pernot MP. Auxologie, m\u00e9thodes et s\u00e9quences. Paris: Theraplix; 1979."},{"issue":"8","key":"2134_CR19","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1097\/00005650-200108000-00006","volume":"39","author":"JW Varni","year":"2001","unstructured":"Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care. 2001;39(8):800\u201312.","journal-title":"Med Care"},{"issue":"6","key":"2134_CR20","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1089\/gtmb.2010.0203","volume":"15","author":"Y Valles-Ayoub","year":"2011","unstructured":"Valles-Ayoub Y, Esfandiarifard S, No D, Sinai P, Khokher Z, Kohan M, et al. Wolman disease (LIPA pG87V) genotype frequency in people of Iranian\u2013Jewish ancestry. Genet Test Mol Biomark. 2011;15(6):395\u20138.","journal-title":"Genet Test Mol Biomark"},{"issue":"10","key":"2134_CR21","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1093\/hmg\/5.10.1611","volume":"5","author":"F Pagani","year":"1996","unstructured":"Pagani F, Garcia R, Pariyarath R, Stuani C, Gridelli B, Paone G, et al. Expression of lysosomal acid lipase mutants detected in three patients with cholesteryl ester storage disease. Hum Mol Genet. 1996;5(10):1611\u20137.","journal-title":"Hum Mol Genet"},{"issue":"4","key":"2134_CR22","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.ymgme.2011.09.006","volume":"104","author":"TM Lee","year":"2011","unstructured":"Lee TM, Welsh M, Benhamed S, Chung WK. Intragenic deletion as a novel type of mutation in Wolman disease. Mol Genet Metab. 2011;104(4):703\u20135.","journal-title":"Mol Genet Metab"},{"issue":"6","key":"2134_CR23","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1111\/petr.12748","volume":"20","author":"S Sreekantam","year":"2016","unstructured":"Sreekantam S, Nicklaus-Wollenteit I, Orr J, Sharif K, Vijay S, McKiernan PJ, et al. Successful long-term outcome of liver transplantation in late-onset lysosomal acid lipase deficiency. Pediatric Transplant. 2016;20(6):851\u20134.","journal-title":"Pediatric Transplant"},{"key":"2134_CR24","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.cca.2021.04.005","volume":"519","author":"A Tebani","year":"2021","unstructured":"Tebani A, Sudri\u00e9-Arnaud B, Boudabous H, Brassier A, Anty R, Snanoudj S, et al. Large-scale screening of lipase acid deficiency in at risk population. Clin Chim Acta Int J Clin Chem. 2021;519:64\u20139.","journal-title":"Clin Chim Acta Int J Clin Chem"},{"issue":"13","key":"2134_CR25","doi-asserted-by":"publisher","first-page":"290","DOI":"10.21037\/atm.2019.05.56","volume":"7","author":"BJ Byrne","year":"2019","unstructured":"Byrne BJ, Fuller DD, Smith BK, Clement N, Coleman K, Cleaver B, et al. Pompe disease gene therapy: neural manifestations require consideration of CNS directed therapy. Ann Transl Med. 2019;7(13):290.","journal-title":"Ann Transl Med"},{"key":"2134_CR26","unstructured":"National Centre for Pharmacoeconomics (NCPE). (2018, 08\/06\/2018). Sebelipase alfa (Kanuma\u00ae). Retrieved 20\/06\/2021, 2021, from http:\/\/www.ncpe.ie\/drugs\/sebelipase-alfa-kanuma\/."},{"key":"2134_CR27","unstructured":"Health CAfDTi. CADTH Common Drug Reviews. Pharmacoeconomic Review Report: Sebelipase Alfa (Kanuma): (Alexion Pharmaceuticals, Inc): Indication: Indicated for the treatment of infants, children, and adults diagnosed with lysosomal acid lipase (LAL) deficiency. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018."},{"issue":"1","key":"2134_CR28","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s13023-019-1129-y","volume":"14","author":"JL Cohen","year":"2019","unstructured":"Cohen JL, Burfield J, Valdez-Gonzalez K, Samuels A, Stefanatos AK, Yudkoff M, et al. Early diagnosis of infantile-onset lysosomal acid lipase deficiency in the advent of available enzyme replacement therapy. Orphanet J Rare Dis. 2019;14(1):198.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"2134_CR29","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1373\/clinchem.2017.282251","volume":"64","author":"S Masi","year":"2018","unstructured":"Masi S, Chennamaneni N, Turecek F, Scott CR, Gelb MH. Specific substrate for the assay of lysosomal acid lipase. Clin Chem. 2018;64(4):690\u20136.","journal-title":"Clin Chem"},{"issue":"1","key":"2134_CR30","first-page":"66","volume":"5","author":"MH Gelb","year":"2019","unstructured":"Gelb MH, Lukacs Z, Ranieri E, Schielen P. Newborn screening for lysosomal storage disorders: methodologies for measurement of enzymatic activities in dried blood spots. Int J Neonatal Screen. 2019;5(1):66.","journal-title":"Int J Neonatal Screen"},{"key":"2134_CR31","doi-asserted-by":"publisher","first-page":"66","DOI":"10.21037\/jlpm.2018.08.04","volume":"3","author":"TM Reynolds","year":"2018","unstructured":"Reynolds TM. A specific substrate assay for lysosomal acid lipase paves the way to neonatal screening and better identification of patients with potentially treatable genetic disease. J Lab Precis Med. 2018;3:66.","journal-title":"J Lab Precis Med"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-02134-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-021-02134-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-02134-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T10:22:04Z","timestamp":1639477324000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-02134-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2134"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-02134-3","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"6 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"507"}}